ImClone C225 Compassionate Use On Hold Pending New Manufacturing Plant

ImClone Systems will consider restarting a compassionate use program for the epidermal growth factor receptor IMC-C225 when production begins at a newly constructed manufacturing plant, CEO Samuel Waksal, MD, told the House Government Reform Committee June 20.